The drug's already controversial OK was made more so for applying to an exceptionally broad patient group. Critics argued the original label would spur use in those unlikely to benefit and balloon Medicare spending.
Original source: https://www.healthcaredive.com/news/fda-biogen-alzheimers-revise-prescribing-information/603027/